CG Oncology, Inc.

NasdaqGS:CGON Stock Report

Market Cap: US$6.1b

CG Oncology Management

Management criteria checks 2/4

CG Oncology's CEO is Arthur Kuan, appointed in Jan 2017, has a tenure of 9.5 years. total yearly compensation is $11.93M, comprised of 5.8% salary and 94.2% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $13.78M. The average tenure of the management team and the board of directors is 2.9 years and 3.8 years respectively.

Key information

Arthur Kuan

Chief executive officer

US$11.9m

Total compensation

CEO salary percentage5.78%
CEO tenure9.5yrs
CEO ownership0.2%
Management average tenure2.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 05

CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade)

Summary CG Oncology has seen significant stock appreciation but now enters a holding pattern with reduced near-term upside potential. Cretostimogene grenadenorepvec remains the lead asset, targeting non-metastatic bladder cancer with pivotal data and a BLA submission expected in 2025-2026. A key upcoming catalyst is the PIVOT-006 topline readout, the first randomized registrational study in intermediate-risk non-muscle invasive bladder cancer. With a strengthened balance sheet and recent fundraising, CGON projects a cash runway extending into the first half of 2029. Read the full article on Seeking Alpha
Analysis Article • Jul 16

We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jan 10

A First Take On CG Oncology

Summary CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Cretostimogene shows superior complete response rates compared to current NMIBC therapies, with a 75% anytime CR and 97% one-year progression-free survival. The competitive landscape includes ImmunityBio's Anktiva and J&J's Gemzar, but CG's clean one-drug profile and strong data make it a potential market leader. A first analysis around CG Oncology follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Summary CG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as a backbone therapy for NMIBC and has shown increased response rates when combined with KEYTRUDA. CG Oncology plans to expand Cretostimogene's use to intermediate-risk NMIBC patients with the phase 3 PIVOT-006 trial, targeting enrollment completion in 1H 2026. The global bladder cancer market size is estimated to reach $8.2 billion by 2032. Read the full article on Seeking Alpha
Seeking Alpha • Aug 26

CG Oncology: Promising Data, But Looks Expensive

Summary CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by selectively replicating in cancer cells and encoding GM-CSF to activate the immune system. The market potential for cretostimogene is significant, targeting BCG-unresponsive NMIBC patients with a multi-billion dollar opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Jul 09

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Summary CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond to the BCG vaccine, but intermediate-risk patients could bring the addressable market above 60,000. Cretostimogene is the company's only asset and there is likely to be significant competition, most likely from Johnson & Johnson. Peak market share of 30% and a $300K sales price at peak can support over $3B in potential revenue and a $54 fair value today. Read the full article on Seeking Alpha
Seeking Alpha • May 06

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Summary CG Oncology, Inc. achieved positive results from its phase 3 BOND-003 study using cretostimogene for the treatment of high-risk BCG unresponsive NMIBC patients; Final data expected end of 2024. Data from phase 3 BOND-003 study turning out positive, could possibly mean an ability for the company to file a New Drug Application to the FDA in 1st half of 2025. A phase 2 study has been initiated, where the combination of cretostimogene + Keytruda is being used to target high-risk BCG-unresponsive NMIBC patients; Data to be released at ASCO 2024. The global bladder cancer market size is projected to reach $7.52 billion by 2030. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Arthur Kuan's remuneration changed compared to CG Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$187m

Dec 31 2025US$12mUS$690k

-US$161m

Sep 30 2025n/an/a

-US$151m

Jun 30 2025n/an/a

-US$128m

Mar 31 2025n/an/a

-US$106m

Dec 31 2024US$11mUS$653k

-US$88m

Sep 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$72m

Dec 31 2023US$4mUS$449k

-US$68m

Sep 30 2023n/an/a

-US$57m

Dec 31 2022US$1mUS$394k

-US$44m

Compensation vs Market: Arthur's total compensation ($USD11.93M) is above average for companies of similar size in the US market ($USD8.33M).

Compensation vs Earnings: Arthur's compensation has increased whilst the company is unprofitable.

CEO

Arthur Kuan (35 yo)

9.5yrs
Tenure
US$11,928,401
Compensation

Mr. Arthur Kuan serves as Chief Executive Officer and Director at CG Oncology, Inc. since 2017 and also serves as Chairman since December 2023 He serves as President at CG Oncology Inc. since May 2026. Mr....

Leadership Team

NamePositionTenureCompensationOwnership
Arthur Kuan
President9.5yrsUS$11.93m0.23%
$ 13.8m
James DeTore
Chief Financial Officerless than a yearUS$785.47kno data
Joshua Patterson
General Counsel2.2yrsUS$2.36mno data
Vijay Kasturi
Chief Medical Officer2.9yrsUS$3.60m0.0015%
$ 91.0k
Swapnil Bhargava
Chief Technical Officer2.8yrsno datano data
Amy Steele
Vice President of Finance & Administration4.5yrsno datano data
Sarah Connors
Vice President of Communications & Patient Advocacyno datano datano data
Bing Kung
Vice President of Corporate Developmentno datano datano data
2.9yrs
Average Tenure
53.5yo
Average Age

Experienced Management: CGON's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arthur Kuan
President9.5yrsUS$11.93m0.23%
$ 13.8m
Leonard Post
Lead Independent Director7.8yrsUS$500.13kno data
Victor Tong
Independent Director3yrsUS$467.63k0%
$ 0
James Mule
Independent Director7.8yrsUS$457.63k0%
$ 0
Susan Graf
Independent Director2.7yrsUS$482.63k0%
$ 0
Brian Liu
Independent Director3.8yrsUS$475.13k0%
$ 0
Christina Rossi
Independent Directorless than a yearUS$575.15kno data
3.8yrs
Average Tenure
51.5yo
Average Age

Experienced Board: CGON's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 21:48
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CG Oncology, Inc. is covered by 19 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Joshua SchimmerCantor Fitzgerald & Co.
Corinne JohnsonGoldman Sachs